PMID- 28635659
OWN - NLM
STAT- MEDLINE
DCOM- 20180323
LR  - 20220331
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 18
IP  - 6
DP  - 2017 Jun 21
TI  - dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and 
      Anti-IgE Therapies.
LID - 10.3390/ijms18061328 [doi]
LID - 1328
AB  - Asthma is an airway disease characterised by chronic inflammation with 
      intermittent or permanent symptoms including wheezing, shortness of breath, chest 
      tightness, and cough, which vary in terms of their occurrence, frequency, and 
      intensity. The most common associated feature in the airways of patients with 
      asthma is airway inflammation. In recent decades, efforts have been made to 
      characterise the heterogeneous clinical nature of asthma. The interest in 
      improving the definitions of asthma phenotypes and endotypes is growing, although 
      these classifications do not always correlate with prognosis nor are always 
      appropriate therapeutic approaches. Attempts have been made to identify the most 
      relevant molecular and cellular biomarkers underlying the 
      immunopathophysiological mechanisms of the disease. For almost 50 years, 
      immunoglobulin E (IgE) has been identified as a central factor in allergic 
      asthma, due to its allergen-specific nature. Many of the mechanisms of the 
      inflammatory cascade underlying allergic asthma have already been elucidated, and 
      IgE has been shown to play a fundamental role in the triggering, development, and 
      chronicity of the inflammatory responses within the disease. Blocking IgE with 
      monoclonal antibodies such as omalizumab have demonstrated their efficacy, 
      effectiveness, and safety in treating allergic asthma. A better understanding of 
      the multiple contributions of IgE to the inflammatory continuum of asthma could 
      contribute to the development of novel therapeutic strategies for the disease.
FAU - Palomares, Oscar
AU  - Palomares O
AD  - Department of Biochemistry and Molecular Biology, School of Chemistry, 
      Complutense University of Madrid, 28040 Madrid, Spain. 
      oscar.palomares@quim.ucm.es.
FAU - Sanchez-Ramon, Silvia
AU  - Sanchez-Ramon S
AD  - Department of Clinical Immunology and Health Research Institute of the Hospital 
      Clinico San Carlos (IdISSC), Hospital Clinico San Carlos, 28040 Madrid, Spain. 
      ssramon@salud.madrid.org.
AD  - Department of Microbiology I, Complutense University School of Medicine, 28040 
      Madrid, Spain. ssramon@salud.madrid.org.
FAU - Davila, Ignacio
AU  - Davila I
AD  - Allergy Service, University Hospital of Salamanca and Institute for Biomedical 
      Research of Salamanca (IBSAL), Biomedical and Diagnosis Science Department, 
      Salamanca University School of Medicine, 37008 Salamanca, Spain. idg@usal.es.
FAU - Prieto, Luis
AU  - Prieto L
AD  - Department of Allergy and Immunology, University of Valencia and Dr. Peset 
      University Hospital, 46017 Valencia, Spain. prieto_jes@gva.es.
FAU - Perez de Llano, Luis
AU  - Perez de Llano L
AD  - Neumology Service, Hospital Universitario Lucus Augusti, 27003 Lugo, Spain. 
      eremos26@hotmail.com.
FAU - Lleonart, Marta
AU  - Lleonart M
AD  - Novartis Farmaceutica, 08013 Barcelona, Spain. marta.lleonart@novartis.com.
FAU - Domingo, Christian
AU  - Domingo C
AD  - Pulmonary Service, Corporacio Sanitaria Parc Tauli, Department of Medicine, 
      Universitat Autonoma de Barcelona (UAB), 08193 Barcelona, Spain. 
      CDomingo@tauli.cat.
FAU - Nieto, Antonio
AU  - Nieto A
AD  - Pediatric Pulmonology & Allergy Unit, Children's Hospital La Fe, 46026 Valencia, 
      Spain. nieto_ant@gva.es.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170621
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Animals
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Asthma/*drug therapy/immunology/physiopathology
MH  - Humans
MH  - Immunoglobulin E/*immunology
MH  - Inflammation/drug therapy/immunology/physiopathology
MH  - Omalizumab/*therapeutic use
PMC - PMC5486149
OTO - NOTNLM
OT  - allergy
OT  - anti-IgE
OT  - asthma
OT  - biological treatment
OT  - biomarkers
OT  - immunoglobulin E (IgE)
OT  - immunological mechanisms
OT  - immunomodulation
OT  - omalizumab
COIS- Silvia Sanchez-Ramon, Ignacio Davila and Oscar Palomares have received speaker 
      fees from Novartis Farmaceutica and participate in the ExIgE group sponsored by 
      Novartis Farmaceutica. Ignacio Davila has additionally participated in advisory 
      boards from Novartis Farmaceutica. Marta Lleonart is employee of Novartis 
      Farmaceutica. The rest of authors do not have any competing interest regarding 
      this manuscript.
EDAT- 2017/06/22 06:00
MHDA- 2018/03/24 06:00
PMCR- 2017/06/01
CRDT- 2017/06/22 06:00
PHST- 2017/03/28 00:00 [received]
PHST- 2017/06/14 00:00 [revised]
PHST- 2017/06/15 00:00 [accepted]
PHST- 2017/06/22 06:00 [entrez]
PHST- 2017/06/22 06:00 [pubmed]
PHST- 2018/03/24 06:00 [medline]
PHST- 2017/06/01 00:00 [pmc-release]
AID - ijms18061328 [pii]
AID - ijms-18-01328 [pii]
AID - 10.3390/ijms18061328 [doi]
PST - epublish
SO  - Int J Mol Sci. 2017 Jun 21;18(6):1328. doi: 10.3390/ijms18061328.